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Abstract
Chemotherapy drugs are administered to patients using combination regimens, and as such the possibility of multiplicative effects 
between drugs need to be investigated. This study examines the individual and combined effects of the chemotherapy drugs cisplatin 
and doxorubicin on the human ovary. Although cisplatin and doxorubicin are known to affect female fertility, there is limited 
information about their direct effects on the human ovary, and none examining the possibility of combined, multiplicative effects of 
co-exposure to these drugs. Here, human ovarian biopsies were obtained from 14 women at the time of caesarean section, with 38 
mouse ovaries also obtained from neonatal C57Bl/6J mice. Tissue was cultured for 6 days prior to analyses, with chemotherapy drugs 
added to culture medium on the second day of culture only. Treatment groups of a single (5 μg/mL human; 0.5 μg/mL mouse) or 
double (10 μg/mL human; 1.0 μg/mL mouse) dose of cisplatin, a single (1 μg/mL human; 0.05 μg/mL mouse) or double (2 μg/mL 
human; 0.01 μg/mL mouse) dose of doxorubicin or a combination of a single dose of both drugs together were compared to controls 
without drug exposure. Exposure to cisplatin or doxorubicin significantly decreased follicle health in human and mouse, supporting 
the suitability of the mouse as a model for the human ovary. There was also a significant reduction of mouse follicle number. Human 
ovarian stromal tissue exhibited increased apoptosis and decreased cell proliferation. Crucially, there was no evidence indicating the 
occurrence of multiplicative effects between cisplatin and doxorubicin.
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Introduction
Women who have been treated with chemotherapy drugs 
for cancer have an increased chance of experiencing 
fertility problems after treatment (Letourneau et al. 2012, 
Barton et al. 2013, Chow et al. 2016, van Dorp et al. 
2018), and a reduced chance of pregnancy (Anderson 
et al. 2018). Given the improving survival rates for most 
cancers, including childhood cancers and those affecting 
younger women, chemotherapy-induced infertility 
is affecting an increasing number of people in our 
population. Despite this, relatively little information is 
available about the effects of chemotherapy drugs on the 
human ovary, with most of our understanding based on 
animal studies or extrapolated from clinical outcomes, 
themselves often using indirect indices of fertility such 
as return of menses after treatment. Chemotherapy 
treatment has been shown to affect follicle health and 
developmental capacity (Asadi Azarbaijani et al. 2015, 
Pampanini et al. 2019). Where information about effects 
of experimental exposure to chemotherapeutics on the 
human ovary is available, it details the effect of exposure 
to a single chemotherapy drug at a time, whereas cancer 
treatment generally involves combination regimens. 
Treatment with multiple drugs is an effective strategy to 
reduce drug resistance and side effects. However, the 
combined effects of exposure to multiple drugs is not 
always predictable, with the possibility of additive or 
even more complex multiplicative effects, a chance that 
can be exacerbated by a large number of potential drug/
dose combinations (Tallarida et al. 1989).
Cisplatin (CIS) and doxorubicin (DOX) are two 
commonly co-administered chemotherapy drugs, used in 
the treatment of a wide range of cancers including breast 
(Di et al. 2016), bladder (Chen et al. 2012), endometrial, 
lung and ovarian (Tas et al. 2008) cancers, as well as in 
lymphoma, neuroblastoma, sarcoma and a range of 
paediatric cancers (Pritchard et al. 2000, Kobys et al. 2013).
There is clear evidence that ovarian exposure to either 
CIS or DOX results in dose-dependent follicle loss and 
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an increase in apoptosis, but the vast majority of our 
knowledge come from animal model studies, primarily 
using a mouse model. Immature oocytes are particularly 
susceptible to CIS exposure, resulting in follicular atresia 
(Morgan et  al. 2013, Tuppi et  al. 2018). The store of 
resting, primordial follicles is reduced after exposure, 
with evidence both of a direct damaging effect of CIS on 
primordial follicles (Nguyen et al. 2018, 2019), and of 
an indirect effect on primordial follicles resulting from 
accelerated activation of primordial follicles due to a 
loss of inhibitory factors previously secreted by more 
developed follicles that have themselves been targeted 
by the drugs (‘burnout’ (Kalich-Philosoph et al. 2013)); 
currently, there is some controversy over the extent 
to which each of these different pathways is primarily 
responsible for the loss of primordial follicles. DOX 
exposure results in a loss of both primordial and growing 
follicles, mainly through effects on mitotically active 
granulosa cells (GCs), and leads to reduced ovulation 
rates (Perez et al. 1997, Ben-Aharon et al. 2010, Morgan 
et al. 2013, Roti Roti et al. 2014). DOX also damages 
ovarian microvasculature and induces necrosis of stroma 
cells (Ben-Aharon et  al. 2010). Direct information 
about the effects of CIS or DOX on the human ovary 
is more limited, but data are available using culture or 
xenotransplantation of human cortical strips and also 
culture of ovarian cells or cell lines. Exposure to either 
CIS or DOX leads to a loss of follicles, including ones 
at the resting primordial stage, with research using 
cultured and xenotransplanted ovarian biopsies exposed 
to CIS (Bildik et al. 2015, 2018) and xenotransplantation 
after treatment with DOX (Soleimani et  al. 2011, Li 
et al. 2014). CIS exposure increases apoptosis of human 
ovarian GCs, as has been shown in work using either 
primary cultures of luteinised GCs (Chatterjee et  al. 
2014, Bildik et al. 2018) or GC lines (Yuksel et al. 2015), 
with Bildik et  al. (2018) also showing a reduction in 
luteinised GC proliferation rates. There are thus no data 
relating to normal, follicular GCs. In addition, CIS and 
DOX both reduce steroidogenic activity (CIS (Chatterjee 
et al. 2014, Bildik et al. 2015, Yuksel et al. 2015) and 
DOX (Imai et al. 2007)).
Less is known about the effect of chemotherapy drugs 
on the stromal compartment of the human ovary, despite 
the fact that damage to stromal tissue, particularly to the 
vasculature, can have a downstream effect on follicle 
health and development (Meirow et  al. 2007). CIS 
and DOX treatments both damage the ovarian stromal 
vasculature (CIS (Bildik et  al. 2015); DOX (Soleimani 
et al. 2011)). Only one study has examined the effects 
of both CIS and DOX in the same system, although that 
research examines the effects of each drug separately, 
with either CIS or DOX inducing apoptosis in cultured 
primary stromal cells (Fabbri et al. 2016).
Here, we examine the effect of CIS and DOX on 
the human ovary through culture of ovarian cortical 
strips, examining the effect of the drugs on both the 
follicular and stromal compartments. Since CIS and 
DOX are often co-administered in treatment, in addition 
to investigating the individual effect of the two drugs, 
we also examine whether there are any additive or 
more complex multiplicative effects when the ovary is 
exposed to both drugs at the same time. To the best of the 
authors’ knowledge, this study is the first to date that has 
examined the combined effects of CIS and DOX on both 
the human ovarian follicular and stromal compartments. 
With the majority of our current understanding about 
the effect of the drugs gained from studies using a mouse 
model and with the limitations inherent in using human 
samples, we also use the same experimental design 
to investigate effects of CIS and/or DOX exposure on 
cultured mouse ovary, to enable comparison of the 
two systems.
Materials and methods
Human ovary tissue
Ovarian cortical tissue samples were collected from 14 healthy 
women aged 27–34 who were undergoing elective caesarean 
section, with written informed consent and approval from 
the Lothian Research Ethics Committee (LREC 10/S1101/2). 
Ovarian tissue was transported to the laboratory in pre-warmed 
Leibovitz L-15 medium (Invitrogen) supplemented with sodium 
pyruvate (2 mM), glutamine (2 mM) (both Invitrogen), HSA 
(3 mg/mL) (Sigma-Aldrich Ltd), 100 U/mL penicillin and 
100 µg/mL streptomycin (P/S; Invitrogen).
Animals
All work was approved by the University of Edinburgh’s Local 
Ethical Review Committee and carried out in accordance with 
UK Home Office regulations. C57Bl/6J mice were housed in 
a 14 h light:10 h dark photoperiod, with access to food and 
water ad libitum.
Human ovary tissue culture
Strips of human ovarian cortex were cultured using a method 
similar to Telfer et  al. (2008). In order to obtain small and 
consistently sized fragments of human ovarian tissue for 
culture, a tissue chopper was used to cut 0.5 mm thick 
sections of the ovarian biopsy, with a scalpel blade then used 
to cut 1 × 1 mm fragments from the sections: this work was 
all carried out in dissecting medium Leibovitz L-15 medium 
with 3 mg/mL human serum albumin (HSA, Sigma-Aldrich 
Ltd), 100 U/mL penicillin and 100 µg/mL streptomycin 
(P/S; Invitrogen), 2 mM L-glutamine (Gibco), 2 mM sodium 
pyruvate (Sigma-Aldrich Ltd), 2 mM sodium pyruvate (Sigma-
Aldrich Ltd). From each ovarian biopsy, at least four ovarian 
fragments were collected and fixed prior to culture. From the 
remaining fragments, each piece was then transferred onto 
Whatman Nucleopore membrane (Camlab Ltd) floating on 
1 mL of medium in a 24-well plate, with the thick (1 × 1 mm) 
side of the fragment placed on to the membrane in order to 
maximise exposure of the tissue to the gas-liquid interphase, 
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and hence, improve tissue viability. Culture was in McCoy’s 
culture medium (Invitrogen) supplemented with 1 mg/mL HSA, 
P/S, 2 mM L-glutamine (Gibco), 5.5 µg/mL transferrin, 5 ng/mL 
sodium selenite, 10 µg/mL human insulin (ITS, Sigma-Aldrich 
Ltd), 50 µg/mL ascorbic acid (Sigma-Aldrich Ltd), 0.005 IU/mL 
FSH (Merk Serono, S.p.A.), and incubated under a controlled 
atmosphere with 5% CO2 at 37°C for 24 h (Day 1). On Day 
2, treatment groups were exposed to chemotherapy drug for 
24 h only, with CIS (Sigma-Aldrich Ltd) or DOX (Sigma-Aldrich 
Ltd) added to culture medium as follows: a single dose of one 
drug (Single CIS – 5 μg/mL; Single DOX – 1 μg/mL), a double 
dose of one drug (Double CIS – 10 μg/mL; Double DOX – 2 μg/
mL), or a combination of a single dose of both drugs together 
(Combination CIS + DOX – 5 μg/mL CIS plus 1 μg/mL DOX). 
From each biopsy, four-to-six pieces of tissue were exposed 
to each treatment, with tissue randomly distributed across the 
treatments. For each analysis of every experimental treatment, 
all technical replicates from one patient were combined to 
give a single datapoint. Tissues were exposed to chemotherapy 
drugs for a short time period, as in previous work by us and 
others, to mimic the short period of exposure that patients 
usually experience each drug cycle (Morgan et al. 2013, Lopes 
et al. 2014, 2016, Lande et al. 2017, Rossi et al. 2017, Smart 
et al. 2018). On Day 3 of culture, after 24 h of drug exposure, 
tissue from experimental treatments was moved to drug-free 
medium for 96 h, with medium changed after 48 h: Control 
tissue was kept in drug-free medium throughout, with medium 
changed at the same time as for experimental groups. For all 
groups, and with medium for all experimental group changed 
on alternative days. For all groups, bromodeoxyuridine (BrdU; 
Sigma-Aldrich Ltd; at a concentration of 15 µg/mL) was added 
to the medium for the final 24 h of culture for subsequent 
determination of cell proliferation. On Day 6 tissues were 
processed for analyses as detailed below. Cultures were 
maintained for 4 days following the day of drug exposure to 
enable histological investigation of the downstream effects of 
drug exposure on follicle health.
Mouse ovary tissue culture
Mouse ovaries were cultured as in Lopes et al. (2016). Ovaries 
were obtained from C57Bl/6J mice at postnatal day 4 and 
dissected into Leibovitz L-15 dissection medium (Invitrogen) 
supplemented with 3 mg/mL BSA (Sigma-Aldrich Ltd). In total, 
38 mouse ovaries were cultured, across four culture runs, with 
five to eight ovaries analysed per treatment group as detailed 
below. Each ovary was transferred into 24-well plates onto 
membranes, as above, floating on 1 mL of α-MEM medium 
(Invitrogen) supplemented with 3 µg/mL BSA and incubated 
under a controlled atmosphere with 5% CO2 at 37°C for 24 h 
(Day 1). On Day 2, CIS or DOX was added as follows: a single 
dose of one drug (Single CIS – 0.5 μg/mL, n = 6 Single DOX – 
0.05 μg/mL, n = 6), a double dose of one drug (Double CIS – 
1 μg/mL, n = 6; Double DOX – 0.1 μg/mL, n = 5), or a combination 
of single doses of both drugs together (Combination CIS + DOX 
– 0.5 μg/mL CIS plus 0.05 μg/mL DOX, n = 8), with Control 
ovaries left in drug-free medium (n = 7). In the mouse model, 
lower drug concentrations were required to induce a similar 
dose response effect to the human tissue, probably due to the 
less compact nature of the mouse ovarian stroma. After 24 h of 
drug exposure, ovaries were moved to drug-free medium (Day 
3), with Control tissue kept in drug-free medium throughout, 
and with medium changed on alternative days until Day 6, 
when tissues were processed for analyses as detailed below. 
Cultures were maintained for 4 days following the day of drug 
exposure to enable histological investigation of the downstream 
effects of drug exposure on follicle health.
Histology
Paraffin wax blocks were sectioned at 5 µm, and either taken 
for immunohistochemistry (IHC; details below) following 
fixation of tissue in Neutral Buffered Formalin (Sigma Aldrich), 
or photomicrographs taken of haematoxylin and eosin-stained 
sections (DMLB Leica microscope, Leica Microsystems Ltd) 
following fixation of tissue in Bouin’s solution (Sigma Aldrich), 
with stained sections used to undertake morphological 
examination of ovarian follicles.
Ovary analysis: follicle counts, stages and health
Photomicrographs of ovarian tissue were examined at every 
tenth (human) or sixth (mouse) section, and used for ovarian 
follicle counts and follicle stage and health assessment using 
ImageJ software by a blind-to-treatment assessor, as detailed 
in Morgan et al. (2013) (Fig. 1). In brief, follicles were staged 
as: primordial, when an oocyte with a visible germinal 
vesicle (GV) was surrounded only by flattened GCs (Fig. 1ai); 
transitional, when an oocyte with a visible GV was surrounded 
by a mixture of flattened and cuboidal GCs (Fig. 1aii); primary, 
when an oocyte with a visible GV was surrounded by a single 
layer of cuboidal GCs (Fig. 1aiii) or secondary, when an oocyte 
with a visible GV was surrounded by more than one layer 
of cuboidal GCs (Fig. 1aiv). Follicles were further classified 
as unhealthy (Fig. 1bi–iv) when containing: an oocyte with 
eosinophilic and shrunk cytoplasm, and/or condensed nuclear 
chromatin; GCs, the majority of which were irregularly shaped 
and/or had condensed chromatin; or those follicles with a 
combination of unhealthy oocytes and GCs.
For human ovary follicle assessment, where cultures had 
been carried out with small sections of an ovarian biopsy, 
follicle density per patient/treatment was then calculated by 
dividing the total number of follicles by the volume of tissue 
analysed and expressing this value as follicles per cubic 
millimetre. For each sample of human ovary, tissue volume was 
calculated as the sum of the area (mm2) of all tissue sections 
analysed multiplied by 0.5 µm (the thickness of each section), 
to give a value in mm3: this number was then multiplied by 
ten, the interval of sections counted, to get total density. Effects 
of drug exposure on follicle density were not examined where 
Control ovarian tissue had a density of less than 20 follicles per 
mm3, with five of the 14 ovarian tissue samples excluded from 
follicle analysis due to the low follicle density, giving a final 
sample size of nine for all human ovarian follicle analyses.
With the mouse ovary follicle assessment, it was possible 
to estimate total follicle numbers per ovary, since cultures 
had been carried out on whole ovaries; estimates of total 
follicle numbers were made by applying the Abercrombie 
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correction to the counts of all visible GV in every sixth section 
(Abercrombie 1946).
Immunohistochemistry
Slides of cultured human ovary were examined to identify 
sections that did not contain ovarian follicles, with reactions 
carried to determine rates of proliferation through IHC for BrdU 
incorporation (rat anti-BrdU antibody, Abcam, dilution 1:200) 
and of apoptosis through IHC for cleaved caspase 3 (CC3; 
rabbit anti-CC3 antibody, Cell Signalling Technology, dilution 
1:500); n = 11 for both. Washes in PBS (Fisher Scientific UK 
Ltd) with 0.1% Triton X (PBSTx) were performed between each 
step. Antigen retrieval was performed in 0.01 M citrate buffer 
(pH 6, Sigma Aldrich Ltd), followed by blocking step with 20% 
normal goat serum diluted in PBSTx and 5% w/v BSA for 1 h 
at RT. Slides were incubated with primary antibodies overnight 
at 4°C in a humidified environment followed by incubation 
with appropriate secondary antibody and visualisation 
reagent all at 1:200 dilution: for BrdU IHC, AlexaFluor 568 
nm goat anti-rat (Invitrogen) was used; for CC3 IHC, goat 
anti-rabbit biotinylated (Vector Laboratories), was followed 
by Streptavidin 488 (Vector Laboratories). Counterstaining 
was with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) 
at 1:5000 for 10 min and slides were then mounted with 
Vectashield hard-set mounting medium (Vector Laboratories).
Image acquisition and analysis
Images were taken using a Leica DM5500B microscope with 
a DFC360FX camera. Image analysis was performed using 
ImageJ, with the assessor blind to treatment. For BrdU and 
CC3 IHC, fluorophore area was measured as a percentage of 
the section area, as in Lopes et al. (2016).
Statistical analysis
Data were analysed using GraphPad Prism. One-way ANOVA 
(for normally distributed data) or the Kruskal–Wallis test (where 
data were not normally distributed) was performed to determine 
if there was an effect of treatment. Where these were significant, 
post hoc tests were carried out to determine statistical 
significance between both between control and different drug 
treatments and also between the combination treatment and 
treatment by a single drug (Single CIS, Double CIS, Single DOX 
or Double DOX), using Dunnet’s or Dunn’s tests respectively. 
All results are given as mean + s.e.m., with results considered 
statistically significant where significance was P < 0.05.
Results
Culture of human ovarian cortical slices supports 
follicle development
Overall, human ovarian strips cultured in an air-medium 
interface remained healthy across the culture period (Fig. 
2B and C), containing follicles at the primordial through 
to the secondary stage. Analyses of follicle density and 
stage showed that the human ovary culture technique 
maintained follicle density (Fig. 2D), while supporting 
follicle development; uncultured ovary tissue contained 
primarily primordial and transitional follicles, while the 
cultured ovary contained mainly primary and secondary 
follicles (Fig. 2E). While follicle health was for the most part 
retained through the culture process (around 80% healthy 
follicles), there was an increase in unhealthy follicles, due 
to a significantly higher percentage of unhealthy primary 
Figure 1 Follicle classification: representative examples of healthy 
and unhealthy human ovarian follicles at different developmental 
stages. Photomicrographs of histological sections of follicles from 
cultured ovaries to show (A) healthy and (B) unhealthy follicles, at the 
(i) primordial; (ii) transitional; (iii) primary or (iv) secondary stage of 
development. White asterisks indicate condensed chromatin; white 
arrowheads indicate shrunk and eosinophilic cytoplasm; scale bars 
represent 25 µm.
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and secondary follicles (P < 0.001; Fig. 2F). Examination 
of histological images showed that unhealthy growing 
follicles in the Control tissue were scattered across the 
whole section area, excluding the possibility that the 
necrosis of the centre of the tissue was responsible for the 
occurrence of unhealthy follicles (Fig. 3).
Damage to ovarian follicles resulting from combined 
exposure to single doses of cisplatin and doxorubicin 
does not exceed that from exposure to each 
drug alone
Exposure to CIS and/or DOX was damaging to ovarian 
follicles in human and mouse ovary. With human ovary 
cultures, results of follicle counts are shown as follicular 
density since analysis is of a small fragment of ovary; 
in contrast, culture of whole mouse ovaries allows for 
analysis of total follicle numbers.
Human ovary appeared to show a trend for drug 
exposure to result in lower follicle density, but there was 
no significant effect overall (Fig. 4ai; P = 0.4). Follicle 
health was affected by drug exposure (Fig. 4bi). There 
was no significant effect on follicle health from exposure 
to a single dose of either drug (Single CIS or Single 
DOX), but, compared to Controls, a significantly higher 
percentage of follicles were unhealthy after exposure 
to Double CIS (2.0-fold difference, P < 0.01), Double 
DOX (2.7-fold difference, P < 0.001) or to Combination 
CIS + DOX (1.8-fold difference, P < 0.05). There was 
no significant difference between the Combination 
CIS + DOX treatment and treatment by CIS or DOX 
alone, either Single or Double dose (Fig. 4ai and bi).
The mouse ovary showed a similar pattern of effect to 
the human ovary, although here there were statistically 
significant effects on follicle numbers (Fig. 4aii) and 
health (Fig. 4bii). Total follicle numbers were significantly 
decreased over those of Controls after exposure to 
Double DOX and to Combination CIS + DOX (Fig. 4aii: 
Double DOX – 2.8-fold difference, P < 0.01; Combination 
CIS + DOX – 3.6-fold difference, P < 0.001). In addition, 
the Combination CIS + DOX treatment was significantly 
different from the Single CIS treatment (Fig. 4aii: 3.0-
fold difference, P < 0.05), but there was no significant 
difference between the Combination CIS + DOX treatment 
and any other treatment group. The percentage of follicles 
classified as unhealthy was increased over that of Controls 
in response to every treatment apart from Single CIS (Fig. 
4bii: Double CIS – 3.0-fold difference, P < 0.01; Single 
DOX – 3.3-fold difference, P < 0.01; Double DOX – 4.1-
fold difference, P < 0.001; and Combination CIS + DOX 
– 3.7-fold difference, P < 0.001). Notably though, the 
Combination CIS + DOX treatment did not lead to greater 
damage than Double CIS, Single or Double DOX, with 
Combination CIS + DOX treatment significantly different 
only to the Single CIS treatment (Fig. 4bii: 2.1-fold 
difference, P < 0.01).
Density/number and health of follicles at specific 
stages following drug exposure
Follicles were classified as being at the primordial, 
transitional or primary/secondary stage, with analysis of 
numbers and the percentages that were healthy. There 
was no significant effect of drug on density of individual 
Figure 2 Effect of culture on human ovarian 
follicles. Culture of cortical strips from human 
ovary for 6 days supports follicles 
development. (A) Slice of ovarian cortex 
floating on a membrane in an air-liquid 
interface culture. (B and C) Representative 
photomicrographs of sections of ovarian tissue 
fixed in Bouin’s and stained with haematoxylin 
and eosin; insets are higher magnification of 
framed areas highlighting group of follicles: (B) 
– uncultured; (C) – cultured. (D, E and F): 
Histograms showing analysis of uncultured 
(white) and cultured (yellow) human ovarian 
tissue: (D) Follicle density (number per mm3); 
(E) Percentage of total follicles that were at 
primordial, transitional or primary/secondary 
stage of development; (F) Percentage of 
follicles that were unhealthy, at primordial, 
transitional and primary/secondary stage of 
development. Scale bars represent 200 µm. 
Histograms: data are mean + s.e.m.; asterisks 
denote significant differences between 
uncultured and cultured ovary – P < 0.01 (**), 
P < 0.001 (***). n = 9 for both uncultured and 
cultured groups. Primord – primordial 
follicles; Trans – transitional follicles; 1°/2° 
– primary/secondary follicles.
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follicle stages in the human ovary at any individual 
follicle stage (Fig. 5ai–iii), although there was a trend for 
the density of primary/secondary follicles to be reduced 
following drug exposure (Fig. 5aiii; P = 0.32). Analysis 
of mouse ovaries showed effects of drug-exposure on 
follicles at all stages when compared with numbers in 
Control ovaries (Fig. 5B). Primordial and transitional 
follicle numbers (Fig. 5bi–ii respectively) were lower 
than Controls only after exposure to Double DOX 
(primordial follicles only: 14-fold difference, P < 0.05) 
or Combination CIS + DOX (primordial follicles – 8-fold 
difference, P < 0.05; transitional follicles – 2.6-fold 
difference, P < 0.05). In contrast, numbers of primary/
secondary follicles were most clearly affected, being 
significantly lower than Controls after exposure to 
every drug treatment (Fig. 5biii: Single CIS – 1.7-fold 
difference, P < 0.05; Double CIS – 2.0-fold difference, 
P < 0.01; Single DOX – 1.9-fold difference, P < 0.01; 
Double DOX – 3.7-fold difference, P < 0.001; and 
Combination CIS + DOX – 3.2-fold difference, 
P < 0.001). No significant difference was found between 
Combination CIS + DOX and treatment by CIS or DOX 
alone, either Single or Double dose, for any ovarian 
follicle stage (Fig. 5bi–iii).
There was a significant effect of drug exposure on 
the percentage of transitional and primary/secondary 
follicles that were healthy, in both human and mouse 
ovaries, while the trend for drug exposure to affect 
the health of primordial follicles was not significant 
(Fig. 6ai: human, P = 0.12; Fig. 6bi: mouse, P = 0.63). 
In the human cultured ovaries, transitional follicles 
exhibited a significant effect on health only after exposure 
to Double DOX (Fig. 6aii: Double DOX – 3.2 fold 
difference, P < 0.05), whereas in the primary/secondary 
follicles, there was an increase in the percentage of 
follicles that were unhealthy after exposure to Double 
CIS, Single DOX or Double DOX (Fig. 6aiii: Double 
CIS and Single DOX – 1.9-fold difference in both cases, 
P < 0.05; Double DOX – 2.5-fold increase, P < 0.001). 
The Combination CIS + DOX treatment was significantly 
different only to the Double DOX treatment, with 
significantly higher percentages of follicles unhealthy 
after exposure to Double Dox (Fig. 6aiii: 1.7-fold 
difference, P < 0.05). In the cultured mouse ovaries, when 
compared with Controls, transitional follicles exhibited 
a significant effect on health after exposure to Single 
DOX, Double DOX and Combination CIS + DOX (Fig. 
6bii: Single DOX – 2.4-fold difference, P < 0.05; Double 
DOX – 3.4-fold difference, P < 0.001; Combination 
CIS + DOX – 2.7-fold difference, P < 0.01), whereas in 
the primary/secondary follicles, there was an increase 
in the percentage of follicles that were unhealthy only 
after exposure to the Combination CIS + DOX treatment 
(Fig. 6biii: Combination CIS + DOX – 4.9-fold increase, 
P < 0.05). The Combination CIS + DOX treatment was 
significantly different from other treatments only for 
transitional follicles in the Single CIS treatment group 
(Fig. 6biii: 2.2-fold difference, P < 0.05).
No specific pattern was observed in terms of cell type 
targeted by the drugs, with either oocyte and/or GCs 
showing signs of degenerations across treatments (Fig. 
7). As with unhealthy follicles in Control sections (Fig. 3), 
unhealthy follicles in drug-exposed sections were found 
to be randomly distributed across the histological sections 
(see Supplementary Fig. 1, see section on supplementary 
materials given at the end of this article, for low power 
Figure 3 Examples of Control sections of cultured human ovarian 
fragments that contain unhealthy follicles. Photomicrographs of 
histological sections from three pieces of Control cultured ovaries, at 
low power (left), with unhealthy follicles shown in insets (right). 
Unhealthy follicles are randomly found throughout the sections, and 
not located in any one region. Black arrowheads indicate atretic 
follicles; scale bars represent 200 µm, or 25 µm for insets.
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images of the drug-exposed sections that contained the 
unhealthy follicles shown in Fig. 3).
Drug exposure leads to changes in apoptosis and 
proliferation in human ovarian stromal tissue
Sections of cultured human ovarian stromal tissue 
that contained no ovarian follicles were examined for 
the effect of CIS and/or DOX on both apoptosis and 
cell proliferation, carrying out IHC for CC3 and BrdU 
respectively (Fig. 8A).
There was a trend for increased expression of CC3 
after drug exposure, although that was significant 
to Controls only after exposure to the Combination 
CIS + DOX treatment (Fig. 8B: Combination CIS + DOX – 
8.5-fold difference, P < 0.01). Amongst treatment groups, 
Combination CIS + DOX treatment was significantly 
different only from the Single DOX treatment (Fig. 8B: 
4.7-fold difference, P < 0.05).
The strongest effect of drug exposure was found 
when investigating cell proliferation, despite the fact 
that the assessment was carried out by determining 
uptake of BrdU (incorporated into any cells entering 
the S-phase of the cell cycle) only during last day 
(Day 6) of culture, with no exposure of the tissue to 
chemotherapy drugs since Day 3. BrdU incorporation 
was significantly lower than that of Control ovaries after 
exposure to Double CIS, Single DOX, Double Dox and 
Combination CIS + DOX (Fig. 8C: Double CIS – 6.2-fold 
difference, P < 0.05; Single DOX – 8.8-fold difference, 
Figure 4 Effect of chemotherapy drug exposure 
on follicle density/number and health. 
Exposure to chemotherapy drugs affects 
follicle number (mouse) and health (human 
and mouse). (A and B): Follicle analysis in 
Control cultures, or after exposure to Single 
CIS, Double CIS, Single DOX, Double DOX or 
Combination CIS + DOX. (A) Density (ai: 
human – unhatched) or number (aii: mouse – 
hatched) of follicles. (B) Percentage of follicles 
that were unhealthy (bi: human – unhatched; 
bii: mouse – hatched). Data are mean + s.e.m.; 
unfilled diamonds denote significant 
differences between Control and a treatment 
group; filled diamonds denote significant 
differences between Combination CIS + DOX 
and another treatment group (individual P 
values are given in text). For human ovaries, 
n = 9 in each group; for mouse ovaries, 5–8 
ovaries were analysed per treatment group as 
follows: Control – n = 7, Single CIS – n = 6, 
Single DOX – n = 6, Double CIS – n = 6, 
Double DOX – n = 5, CIS + DOX – n = 8). 
Comb – Combination.
Figure 5 Effect of chemotherapy drug exposure 
on follicle density/number at each follicular 
stage. Follicle analysis in Control cultures, or 
after exposure to Single CIS, Double CIS, 
Single DOX, Double DOX or Combination 
CIS + DOX. (A) Density (human – unhatched) 
or (B) number (mouse – hatched) of follicles at 
(ai, bi) Primordial, (aii, bii) Transitional and 
(aiii, biii) Primary/Secondary stage. Data are 
mean + s.e.m.; unfilled diamonds denote 
significant differences between Control and a 
treatment group (individual P values are given 
in text). For human ovaries, n = 9 in each 
group; for mouse ovaries, 5–8 ovaries were 
analysed per treatment group as follows: 
Control – n = 7, Single CIS – n = 6, Single DOX 
– n = 6, Double CIS – n = 6, Double DOX 
– n = 5, CIS + DOX – n = 8). Primord – 
primordial follicles; Trans – transitional 
follicles; 1°/2° – primary/secondary follicles; 
Comb – Combination.
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P < 0.01; Double DOX – 10.2-fold difference, P < 0.001; 
Combination CIS + DOX – 7.7-fold difference, P < 0.01). 
Amongst treatment groups, Combination CIS + DOX 
treatment was significantly different only to the Single 
CIS treatment (Fig. 8C: 4.7-fold difference, P < 0.05).
Discussion
It has long been recognised that chemotherapy treatment 
can result in reduced fertility for females. However, 
clinical information predominantly comes from patients 
who are administered complex combinations of drugs, 
while the literature mainly examines direct effects of the 
drugs on the ovary, using the mouse as a model, and 
with a lack of investigations into potential combinatory 
effects of chemotherapy drugs. Here, we show the 
effects of exposing the human ovary to CIS and/or DOX, 
through use of a tissue culture system that we show is 
able to support the development and growth of early 
stage human ovarian follicles. The work investigated the 
impact of the chemotherapy drugs on both the follicular 
and stromal ovarian compartments, and examined the 
Figure 6 Effect of chemotherapy drug exposure 
on follicle health at each follicular stage. 
Follicle analysis in Control cultures, or after 
exposure to Single CIS, Double CIS, Single 
DOX, Double DOX or Combination 
CIS + DOX. (A and B) Percentage of follicles 
that are unhealthy; (A) human – unhatched; (B) 
mouse – hatched, at (ai, bi) Primordial, (aii, 
bii) Transitional and (aiii, biii) Primary/
Secondary stage. Data are mean + s.e.m.; 
unfilled diamonds denote significant 
differences between Control and a treatment 
group; filled diamonds denote significant 
differences between Combination CIS + DOX 
and another treatment group (individual P 
values are given in text). For human ovaries, 
n = 9 in each group; for mouse ovaries, 5–8 
ovaries were analysed per treatment group as 
follows: Control – n = 7, Single CIS – n = 6, 
Single DOX – n = 6, Double CIS – n = 6, 
Double DOX – n = 5, CIS + DOX – n = 8. 
Primord – primordial follicles; Trans – 
transitional follicles; 1°/2° – primary/
secondary follicles; Comb – Combination.
Figure 7 Histological images of unhealthy 
follicles exposed to chemotherapy drugs. 
Photomicrographs of histological sections of 
follicles from cultured ovaries that have been 
exposed to chemotherapy drugs. Follicles had 
been exposed to: (ai) Single CIS, (bi–iv) 
Double CIS, (ci–iv) Single DOX, (di–iv) 
Double DOX or (ei–iv) Combination 
CIS + DOX. Yellow arrowheads indicate shrunk 
and eosinophilic cytoplasm; yellow asterisks 
indicate condensed chromatin; scale bars 
represent 25 µm.
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combined effects of CIS and DOX by comparing the 
effect of exposure to single or double doses of CIS or 
DOX alone with exposure to a combination treatment 
of a single dose of CIS + DOX. While exposure to either 
CIS or DOX alone reduced ovarian health, there was no 
evidence of any multiplicative effects when ovaries were 
cultured in a combined CIS + DOX treatment. Effects 
of treatment had a similar pattern in the mouse ovary, 
both qualitatively and quantitatively; however, here 
differences more often reached statistical significance, 
supporting the value of the mouse as a model for the 
human ovary for toxicological studies. Given the 
importance of the stromal compartment of the ovary, 
and the relatively high proportion of the human ovary 
that is composed of stromal tissue, the effect of the drugs 
on human ovarian cortical stromal tissue was evaluated: 
drug treatment resulted in increased apoptosis, and in a 
striking reduction in cell proliferation.
CIS is a platinum-based alkylating-like agent, usually 
considered to have moderate-to-high gonadotoxicity. It 
acts by inducing DNA cross-linking that results in the 
formation of adducts which interfere with DNA repair and 
block cell division: together this leads to DNA damage, 
inducing apoptosis (Dasari & Tchounwou 2014). It has 
been suggested that CIS also interferes with nuclear 
and cellular proteins connected with its long-term toxic 
effects (Chovanec et al. 2017). DOX is an anthracycline 
and an inhibitor of topoisomerase II (Topo II); clinically, 
the range of reported gonadotoxicity for DOX is wide 
(Ben-Aharon et al. 2010, Soleimani et al. 2011). DOX 
inhibits Topo II by inhibiting resealing cleaved DNA, 
thus leading to increased DNA fragmentation and hence 
cell death (Kiyomiya et al. 1998, Thorn et al. 2011). DOX 
also acts on mitochondria, reducing both mitochondrial 
membrane potential and cytochrome C release.
Modern chemotherapy treatment involves the 
combined administration of multiple drugs. Combination 
therapy has proved key to improving treatment efficiency, 
likely due to the different drugs targeting differing 
pathways, thus resulting in additive or even synergistic 
effects (Bayat Mokhtari et al. 2017). For CIS and DOX in 
particular, the addition of DOX has proved to increase 
significantly CIS cytotoxicity on cancer cells, with both 
clinical studies on cancer patients (Bruckner et  al. 
1981) and also in vitro studies using cancer cell lines 
(Xu et  al. 1989) showing that CIS and DOX can have 
additive effects: hence, their common combined use. 
However, less is known about any potential undesired 
consequences of such a multi drug regimen, in particular 
on female fertility, and it is important to bear in mind that 
any off-target effects resulting from combined treatment 
could be more severe (Calabrese 1995, Delbaldo et al. 
2004). Here, no multiplicative effects on the ovary were 
found: in no case did exposure to a combined single 
dose of CIS and DOX together result in more severe 
damage than that found after exposure to a double dose 
of either CIS or DOX alone.
Treatment with either CIS or DOX resulted in a 
reduction in follicle number and increase in the 
percentage of unhealthy follicles in human and mouse 
ovary, with significant effects on the number and health 
of the total follicle population. This was due to an effect 
on the population of growing follicles in particular. These 
results are consistent with previous work, and add to the 
limited number of publications investigating effects of 
CIS or DOX on the human ovary. In the human ovary, 
CIS has been shown to affect follicle number in cultured 
ovarian cortical strips and in xenotransplantations 
(Bildik et  al. 2015, 2018) and results in increased 
apoptosis in cultured luteinised GCs (Chatterjee et  al. 
2014, Yuksel et al. 2015, Bildik et al. 2018), while DOX 
leads to a reduction in follicle numbers and increase in 
the number of atretic follicles in xenotranplanted human 
ovarian cortical tissue (Soleimani et  al. 2011, Li et  al. 
2014). The majority of our information about the effects 
of CIS or DOX on the ovary comes from studies using the 
mouse as a model. CIS results in oocyte damage (Kim 
et al. 2013, Nguyen et al. 2019), with oocytes activating 
c-ABL and in turn the oocyte-specific homologue of 
p53, Tap63, that mediates the oocyte’s DNA damage 
Figure 8 Apoptosis and cell proliferation in cultured human ovary exposed to chemotherapy drugs. Exposure of human ovary to chemotherapy 
drugs increases apoptosis and reduces cell proliferation. (A) Representative photomicrograph of cultured human ovary (inset is higher 
magnification of framed area), showing immunohistochemical localisation of cleaved caspase 3 (CC3) (green) and BrdU (red), counterstained 
with DAPI (blue). (B and C) Graphs show protein expression calculated as a percentage of area of ovary for (B) CC3 and (C) BrdU after exposure 
to Single CIS, Double CIS, Single DOX, Double DOX or Combination CIS + DOX. Scale bar represents 200 µm. Data are mean + s.e.m.; unfilled 
diamonds denote significant differences between Control and a treatment group; filled diamonds denote significant differences between 
Combination CIS + DOX and another treatment group (individual P values are given in text). Sample size: n = 11 in all groups. Comb – 
Combination.
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response (Gonfloni et al. 2009, Gonfloni 2010, Bolcun-
Filas et al. 2014, Rinaldi et al. 2017, Nguyen et al. 2018, 
Kim et  al. 2019). CIS also increases phosphorylation 
of components of the PTEN/Akt/FOXO3a pathway 
that regulates growth activation of primordial follicles 
(Chang et al. 2015, Jang et al. 2016). DOX induces DNA 
damage in somatic cells (Roti Roti et  al. 2012, 2014, 
Xiao et al. 2017).
Apoptosis and proliferation of ovarian cortical 
stromal tissue was affected by drug exposure. As with 
the follicular compartment, there was no evidence 
of any multiplicative effect between the two drugs, 
although only the co-treatment of CIS and DOX induced 
a significant increase in apoptosis in the stromal tissue 
compared to that of Controls. The effect on stromal 
tissue was most pronounced when examining cell 
proliferation, with a dramatic reduction in proliferating 
cells after exposure to all drug treatments other than 
Single CIS treatment. Notably, this was despite the fact 
that exposure to the drugs had ended 96 h prior to 
tissue examination, with all tissue maintained in drug-
free medium throughout that 96-h period. Effects on 
apoptosis in human ovarian cells have been described 
previously, with Fabbri et al. (2016) showing effects of 
both CIS and DOX on cultured primary stromal cells, and 
Bildik et al. (2018) demonstrating increased apoptosis in 
cultured luteinised granulosa cells. Both CIS and DOX 
have also been shown to damage the stromal vasculature 
(Meirow et al. 2007, Soleimani et al. 2011, Bildik et al. 
2015). To the best of the authors’ knowledge, this is the 
first report on effects of CIS or DOX on human stromal 
cell proliferation, with the effects of chemotherapy 
drugs on the stromal component of the ovary examined 
relatively little to date (Spears et al. 2019). A decrease 
in stromal cell proliferation could result in reduced 
formation of thecal cell layers in developing follicles, or 
of neoangiogenesis, either of which would compromise 
follicle growth and development.
The effects of CIS and/or DOX on ovarian follicles 
was examined both in the human and also the mouse 
ovary in order to assess how effective the mouse ovary is 
as a model of the human ovary. The same experimental 
paradigm was used in each case, exposing ovaries 
to single or double doses of each drug alone, or to a 
combination treatment of a single dose of both CIS and 
DOX together. Lower drug concentrations were required 
for the mouse ovary compared to the human ovary to 
induce similar levels of damage, most likely due to the 
lower density of stromal compartment in mouse ovary. 
CIS was administered at 5 or 10 μg/mL (equivalent to 
16.7 or 33.4 μM) in the human ovary cultures, and to 
0.5 or 1.0 μg/mL in the mouse; DOX exposure was to 1 
or 2 μg/ml (equivalent to 1.7 or 3.4 μM) in the human 
ovary cultures, and to 0.05 or 0.1 μg/mL in the mouse. 
This compares to concentrations of 20–40 μg/mL of CIS 
(Bildik et  al. 2015, 2018) and 1, 10 or 100 μg/mL of 
DOX (Soleimani et al. 2011) previously used in human 
ovarian cortical tissue culture. Overall, the same pattern 
of effect was found in the human and mouse ovary, 
with statistically significant effects more frequent in the 
mouse ovary study than in the human. The increased 
statistical power of the mouse study is most likely due 
to the use of an inbred strain of mouse, compared to the 
challenging variability in the samples of human ovarian 
tissue. In addition, cultures of neonatal mouse ovary 
can use intact, whole ovaries, enabling estimations of 
total follicle numbers, whereas samples of human ovary 
require analysis of follicle densities, despite the high 
variability in follicle density across the human ovary. 
Taken together, this points to the suitability of using the 
mouse as a model in studies such as these.
In summary, this study examines the individual and 
combined effects of two commonly co-administered 
chemotherapy drugs, cisplatin and doxorubicin, using 
both human and mouse ovarian tissue. Cisplatin and 
doxorubicin both impacted on the health of ovarian 
follicles and stromal tissue, with results in the mouse 
study closely mirroring those using human tissue, giving 
weight to use of the mouse as a model species in these 
kinds of toxicological studies. Importantly, no evidence 
was found of any multiplicative effects between the 
two drugs.
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